A Phase 4 interventional study of eletriptan in Migraine, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 6 sites in Turkey. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Phase 4, Interventional, and Treatment
To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)
1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.
This study's enrollment of 120 is above the median of 80 across 1,175 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 431 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: eletriptan
40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response
Headache severity and response post-treatment
Time frame: 2 hours
Functional response post-treatment
Time frame: 2 hours
Presence of associated symptoms including, nausea, vomiting, phonophobia, and photophobia at baseline and post-treatment
Time frame: 1, 2, 4, and 24 hours
Migraine recurrence post-treatment
Time frame: 1, 2, 4, and 24 hours
Time loss (from normal activities and from work) post-treatment
Time frame: 24 hours
Subject preference and acceptability post-treatment
Time frame: 24 hours and 12 weeks
Subject satisfaction post-treatment
Time frame: 2 and 24 hours
Adverse events
Time frame: Week 12
Physical examination
Time frame: Week 12
Vital signs
Time frame: Week 12
Electrocardiogram
Time frame: Week 12
Headache severity and response at baseline and post-treatment
Time frame: 1, 4 and 24 hours
Functional impairment severity and response at baseline and post-treatment
Time frame: 1, 4 and 24 hours
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.